Has the current pandemic climate created a conservative approach to your non-essential business purchases this year? Rigaku and our exceptional financing partner, NewLane Finance, are offering our customers* a very special relief offer in order to allow pharmaceutical companies to maintain pre-pandemic, long-term, and quality strategies.

Don’t let temporary COVID-related freezes in purchasing stand in the way of your organization’s readiness for what is to come:

• 12 monthly payments at $99/month (plus a one-time document fee of $149.) Only $1,337 owed in the first FULL YEAR!
• Then choose from a variety of options from 1–5 year terms thereafter.
• If you want, pay off the principal on your Progeny with no penalty on the thirteenth month.

Align your implementation timelines with budget timelines and be ready to put your Progeny into qualified release testing at the same time you’re ready to pay it off. Demonstrate huge ROI potential to your management team by using the low-cost first year to validate the solution onsite.

* Customers based in the U.S. only

The COVID-19 global situation may have paused your capital purchases until now, but if your organization can see the light at the end of the tunnel, be ready for it with Rigaku financing!